Details for Patent: 6,875,872
✉ Email this page to a colleague
Title: | Compounds |
Abstract: | The novel optically pure compounds Na.sup.+, Mg.sup.2+, Li.sup.+, K.sup.+, Ca.sup.2+ and N.sup.+ (R).sub.4 salts of (+)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H- benzimidazole or (-)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H- benzimidazole, in particular sodium and magnesium salt form thereof, where R is an alkyl with 1-4 carbon atoms, processes for the preparation thereof and pharmaceutical preparations containing the compounds as active ingredients, as well as the use of the compounds in pharmaceutical preparations and intermediates obtained by preparing the compounds. |
Inventor(s): | Lindberg; Per Lennart (Molndal, SE), Von Unge; Sverker (Fjaras, SE) |
Assignee: | AstraZeneca (Sodertalje, SE) |
Filing Date: | Oct 16, 2000 |
Application Number: | 09/690,044 |
Claims: | 1. Magnesium salt of (-)-5-methoxy-2-[[(4-methoxy-3,5,dimethyl-2-pyridinyl)methyl]sulfinyl]-1H- benzimidazole in an optical purity of at least about 94% enantiomeric excess. 2. The compound according to claim 1, when the optical purity is at least 94% enantiomeric excess. 3. The compound according to claim 1 or 2, wherein the compound is in crystaline form. 4. Magnesium salt of (-)-5-methoxy-2-[[(4-methoxy-3,5,dimethyl-2-pyridinyl)methyl]-sulfinyl]-1H -benzimidazole in an optical purity of at least about 98.4% enantiomeric excess. 5. The compound according to claim 4, wherein the optical purity is at least 98.4% enantiomeric excess. 6. The compound according to claim 4 or 5, wherein the compound is in crystaline form. 7. Magnesium salt of (-)-5-methoxy-2-[[(4-methoxy-3,5,dimethyl-2-pyridinyl)methyl]-sulfinyl]-1H -benzimidazole in an optical purity of at last about 99.8% enantiomeric excess. 8. The compound according to claim 7, wherein the optical purity is at least 99.8% enantiomeric excess. 9. The compound according to claim 7 or 8, wherein the compound is in crystalline form. 10. Magnesium salt of (-).sub.5 -methoxy-2-[[(4-methoxy-3,5,dimethyl-2-pyridinyl)methyl]-sulfinyl]-1H-benz imidazole in an optical purity of at least about 99.9% enantiomeric excess. 11. The compound according to claim 10, wherein the optical purity is at least 99.9% enantiomeric excess. 12. The compound according to claim 10, wherein the compound is in crystalline form. |